The 'Dancing with the Stars' contestant lost 20 lbs. from a GLP-1 medication but stopped taking it after experiencing ...

The META-AF trial found fewer recurrences of atrial arrhythmias, a benefit unexplained by weight loss or glycemic control.

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Last year, the U.S. Food and Drug Administration banned the sale of compounded weight loss drugs, which are often much ...

"Developing new ways to treat these patients is of the utmost importance," Dr. Casey H. Halpern, a senior author of the study ...

The results show the treatment's potential to mitigate GLP-1 induced nausea and vomiting, which are key factors for those who stop using weight-loss drugs, Vanda Chief Executive Mihael Polymeropoulos ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

A banned weight-loss drug with dangerous cardiac side-effects is being marketed to young people as a natural supplement on ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...